Abstract:Abstract Immune checkpoint blockade (ICB) targeting PD-1/PD-L1 has emerged as a revolutionizing treatment modality for multiple cancers. However, durable remission and objective response rates with ICB monotherapy remain low. Several immune resistance mechanisms have been revealed and used to develop combinational therapy. In consideration of the durable and impressive responses observed in ‘hot’ tumors, it will be valuable to make an endeavor to elucidate the tumor evasion mechanisms. Despite the well-established mechanisms in immunotherapy resistance, our study uncovered a new mechanism of tumor immune evasion through the RNA-binding protein HuR/CD147 axis. The RNA-binding protein Hu antigen R (HuR) is overexpressed in a variety of cancers and promotes tumorigenesis by interacting with a subset of oncogenic mRNAs. The tumor-associated antigen CD147, a highly glycosylated transmembrane immunoglobulin, is widely and specifically expressed in multiple malignancies. We phenotypically observed the downregulation of CD147 in HuR-deficient cells and elucidated that HuR regulates CD147 mRNA via binding to the AU-rich elements of its 3' UTR. The direct binding of HuR to CD147 mRNA in multiple types of cells was validated by Ribonucleoprotein immunoprecipitation (RNP-IP) and RNA pulldown assay. These data together clarify HuR is engaged in CD147 post-transcription regulation. KH-39 is a HuR-specific small molecule inhibitor, which disrupts the HuR function by competing for the binding site with its target mRNAs. KH-39 treatment reduced CD147 level in a time-/dose-dependent manner. We also tested the anti-tumor action of HuR small molecular inhibitor KH-39 in tumor proliferation, clonogenicity, cell death, cytokine secretion, and in vivo tumor growth. The cytokine array assay indicated multiple immune-related cytokines changed after HuR inhibition and CD147 knockdown, including IL-6, which is proven to act as an immunomodulating agent in the tumor microenvironment. These data demonstrated the potential mechanism of overcoming immunoresistance by inhibiting the HuR/CD147/IL-6 axis. To test the combination strategy using HuR inhibitor and anti-PD-1 antibody in vivo, we established the EMT6 orthotopic mouse breast cancer model. A combination of HuR inhibitor KH-39 and anti-PD-1 antibody enhanced the anti-PD1 immunotherapy response and prolonged survival compared to the single agent group. Taken together, we preliminarily explored the HuR/CD147/IL-6 axis in tumor immune evasion, which might be a promising therapeutic target to overcome immune evasion and improve immunotherapy response in cancer. This finding may have reference significance for clinical cancer therapy. Citation Format: Qi Zhang, Lauren Dandreo, Xiaoqing Wu, Liang Xu. Inhibition of HuR/CD147/IL-6 axis enhances anti-PD1 immunotherapy response in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6646.

The RNA-binding protein HuR in human cancer: A friend or foe?

Targeting the RNA-binding protein HuR in cancer.

Multiple Functions of the RNA-Binding Protein HuR in Cancer Progression, Treatment Responses and Prognosis

The Role of RNA-Binding Protein HuR in Lung Cancer by RNA Sequencing Analysis

HuR, a Key Post-Transcriptional Regulator, and Its Implication in Progression of Breast Cancer.

HuR Affects the Radiosensitivity of Esophageal Cancer by Regulating the EMT-Related Protein Snail

The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer

An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis

Loss of Repression of HuR Translation by Mir‐16 May Be Responsible for the Elevation of HuR in Human Breast Carcinoma

RNA-binding protein HuR inhibition induces multiple programmed cell death in breast and prostate cancer

Identification of tumorigenesis-related mRNAs associated with RNA-binding protein HuR in thyroid cancer cells

HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment

Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis

Unraveling the Regulatory Role of HuR/microRNA Axis in Colorectal Cancer Tumorigenesis

Small Molecules Targeting the RNA-Binding Protein HuR Inhibit Tumor Growth in Xenografts

HuR (ELAVL1) Stabilizes SOX9 mRNA and Promotes Migration and Invasion in Breast Cancer Cells

The expression of human antigen R and vascular endothelial growth factor-C and their significance in non-small cell lung cancer]

Evaluation of Expression of UHRF1 and Its Prognostic and Clinicopathological Value in Human Malignancies: A Systematic Review and Meta-analysis

Abstract 6646: Inhibition of HuR/CD147/IL-6 axis enhances anti-PD1 immunotherapy response in cancer

The Expression of RNA-Binding Protein HuR in Non-Small Cell Lung Cancer Correlates with Vascular Endothelial Growth Factor-C Expression and Lymph Node Metastasis